Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Protein Expression and Purification|June 10, 2008
Refinement in the production and purification of recombinant HCMV IE1-pp65 protein for the generation of epitope-specific T cell immunityThi H O Nguyen, Nicole A Mifsud, Lisbeth A Stewart, et al.
Blood|May 3, 2002
Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantationCharles G Mullighan, Sue Heatley, Kathleen Doherty, et al.
Blood|June 17, 2008
Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantationCharles G Mullighan, Susan L Heatley, Silke Danner, et al.
The Journal of Antimicrobial Chemotherapy|October 24, 2025
Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trialChin Fen Neoh, Michelle K Yong, Leesa Rowley, et al.
Hemasphere|November 15, 2019
A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AMLAnthony P Schwarer, Jason Butler, Kathryn Jackson, et al.
The Journal of Molecular Diagnostics : JMD|July 22, 2017
A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with LeukemiaIlaria S Pagani, Chung H Kok, Verity A Saunders, et al.
Blood|June 21, 2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibTimothy P Hughes, Jeffrey H Lipton, Nelson Spector, et al.
Blood|July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsSusan Branford, Zbigniew Rudzki, Ian Parkinson, et al.
Blood|May 25, 2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M Ross, Susan Branford, John F Seymour, et al.
British Journal of Haematology|May 28, 2020
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Pageof 4